<p>This review offers a comprehensive and insightful overview of the production of therapeutic radionuclides (³²P, ⁸⁹Sr, ^117mSn, ¹⁵³Sm, ¹⁶⁶Ho, ¹⁸⁶Re, ¹⁸⁸Re, ¹⁷⁷Lu and ²²³Ra), which are essential for developing bone-targeting radiopharmaceuticals. These radionuclides are critical not only in the early stages of radiopharmaceutical development but also in ensuring their continued success, reliability, and progress. The manuscript highlights recent innovations and trends in the field, addressing significant challenges and emerging opportunities. It also examines the regulatory environment and emphasizes the growing role of automation in enhancing the production process.</p>